Golden Seeds company EliseAI just announced the completion of their Series D funding at a post-money valuation of over $1 billion. EliseAI is the largest and most advanced conversational AI platform for the housing industry and expanded into healthcare in 2023. The company uses AI to increase the ability of these sectors to serve more people and to elevate the quality of the service they provide to consumers, enhancing the lives of millions. Read more here.
8/14/24
Golden Seeds company EliseAI recently announced they are now available on the athenahealth Marketplace. This milestone marks a significant step forward in their mission to revolutionize healthcare through cutting-edge AI technology. Read more here.
7/22/2024
Golden Seeds company Bone Health Technologies, a leading medical technology innovator developing breakthrough non-pharmacological solutions to improve bone health and reduce fractures, recently announced the acquisition of Wellen, a Brooklyn-based health technology company reinventing exercise-based osteoporosis care as a personalized and science-backed solution. Read more here.
7/25/24
Golden Seeds company Uncaged Innovations has raised $5.6 million in seed funding to commercialize its bio-based, plastic-free leather made from grains. The round was led by Green Circle Foodtech Ventures and Fall Line Capital, with participation from Ponderosa Ventures, Golden Seeds and Jaguar Land Rover’s investment arm InMotion Ventures. Read more here.
7/2/24
Golden Seeds company Sylvatex announced CEO Virginia Klausmeier as the first recipient of the Fastmarkets Voltas Industry Woman of the Year Award. The award, sponsored by ExxonMobile, was presented at the Lithium Supply and Battery Raw Materials Conference. Read more here.
6/26/24
Golden Seeds company Concerto Biosciences announced that the U.S. FDA has cleared its Investigational New Drug application to initiate a Phase 1, first-in-human trial of Ensemble No.2 (ENS-002), an investigational live biotherapeutic product to treat atopic dermatitis. Read more here.
6/26/24
Materna Medical Inc. has completed the first close of a $20 million Series B2 financing round led by InnovaHealth Partners and participation from other key existing investors, including Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, Golden Seeds, Band of Angels, and Houston Angel Network. Read more here.
6/25/24
Golden Seeds company NX Prenatal announced a new clinical study that demonstrates the company’s first-trimester pre-term birth test’s ability to predict the risk of spontaneous pre-term birth (sPTB) in nulliparous pregnant women. The study was published recently in the American Journal of Obstetrics and Gynecology. Read more here.
6/20/24
Golden Seeds company Day Zero Diagnostics recently revealed a new approach to antimicrobial susceptibility testing using artificial intelligence (AI) to guide analysis. The system, Keynome gAST, analyzes bacterial whole genomes extracted from patient blood samples, eliminating the need for culture growth. Read more here.
6/14/24
